Fig. 1: Sapanisertib pharmacokinetics are dose dependent without plasma accumulation over time. | British Journal of Cancer

Fig. 1: Sapanisertib pharmacokinetics are dose dependent without plasma accumulation over time.

From: Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

Fig. 1

Mean (SD) plasma concentration–time profiles of multiple-dose sapanisertib (cycle 2, day 1) on the a QD, b QW, c QD × 3dQW and d QD × 5dQW dosing schedules. Error bars indicate SD. QD once daily, QD × 3dQW QD for 3 days on/4 days off QW, QD × 5dQW QD for 5 days on/2 days off QW, QW once weekly, SD standard deviation.

Back to article page